The present invention provides a method and a dietary composition for prevention and regulation of obesity capable of obtaining efficacy such as required appetite suppression or satiety by having a positive effect on concentrations of neurotransmitters such as serotonin, dopamine, and norepinephrine which are the principle of a mechanism of appetite inhibitory drugs without prescription of medicines (Phentermine, Prozac, etc.) and further being used as an alternative diet and supplying a protein that is the most lack ingredient during diet. The dietary composition includes tryptophan, which is one amino acid, tyrosine, which is the other amino acid, rhodiola, which is one herb, chamomile, which is the other herb, and a whey protein as active ingredients.

The present disclosure relates to a Bacillus amyloliquefaciens CJ14-6 strain isolated from traditional meju, a preparation method for soybean koji using the same, and a soybean koji prepared by the preparation method. The preparation method for soybean koji includes: soaking soybeans in water or adding waster to soybeans and steaming the soaked soybeans; and inoculating a Bacillus amyloliquefaciens CJ14-6 strain into the steamed soybeans, fermenting the steamed soybeans, and drying the fermented soybeans to prepare a soybean koji.

The present disclosure relates to a Bacillus amyloliquefaciens CJ14-6 strain isolated from traditional meju, a preparation method for soybean koji using the same, and a soybean koji prepared by the preparation method. The preparation method for soybean koji includes: soaking soybeans in water or adding waster to soybeans and steaming the soaked soybeans; and inoculating a Bacillus amyloliquefaciens CJ14-6 strain into the steamed soybeans, fermenting the steamed soybeans, and drying the fermented soybeans to prepare a soybean koji.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

There is provided a novel Lactobacillus fermentum strain (Accession No. KCTC 14105BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation in white adipose tissue and increase anti-inflammatory cells. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus fermentum strain may regulate a concentration of metabolic hormones and adipokines in blood. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent and treat a metabolic disease such as obesity.

There is provided a novel Lactobacillus fermentum strain (Accession No. KCTC 14105BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation in white adipose tissue and increase anti-inflammatory cells. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus fermentum strain may regulate a concentration of metabolic hormones and adipokines in blood. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent and treat a metabolic disease such as obesity.

The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. In addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.

The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. In addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.